SRI International awarded contract for NCI PREVENT program

SRI INTERNATIONAL was awarded a contract of up to $9 million to provide preclinical development services to the NCI PREVENT Cancer Program.

Under the contract, SRI will provide scientific expertise, modern testing and support facilities, and analytical instrumentation to conduct a wide variety of preclinical pharmacology and toxicology studies to evaluate potential cancer prevention drugs.

The PREVENT Cancer Drug Development Program is an NCI-supported pipeline to bring new cancer preventing interventions and biomarkers through preclinical development towards clinical trials. PREVENT enables milestone-driven progression of novel cancer preventive chemical or biological agents and biomarkers from the laboratory bench towards proof-of-principle clinical testing and registration or validation.

The current contract calls for SRI to deliver high-quality laboratory data to support NCI-PCP’s efforts to develop promising therapeutic candidates such as vaccines and cancer chemopreventive agents that will inhibit, delay or reverse manifestations of cancer. SRI will be responsible for managing therapeutic candidates from conception to submission of an Investigational New Drug application to FDA.

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

In The Headlines: Increasing incidence of early-onset cancer is “a paradigm shift oncology isn’t quite prepared for”

“Your entire practice, cancer has been associated with an aging population, and then you have a young, beautiful, healthy-looking woman like Alisa Secaida come into your office, it's not a surprise that the doctor, their knee-jerk reaction would be like, ‘Maybe just slow down,’” said The Cancer Letter’s Claire Marie Porter.

June 11, 2025

Vol.51 No.22

Clinical

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

For more than a year before her stage 4 lung cancer was found, 35-year-old Alisa Secaida, a never-smoker and a physically active Southern Californian, had been experiencing a persistent cough and, increasingly, fatigue.

June 06, 2025

Vol.51 No.22

By Claire Marie Porter

Reimagining cancer care for a new generation of patients

The landscape of cancer is shifting beneath our feet, and we must adapt our clinical practice accordingly.

June 06, 2025

Vol.51 No.22

By Hope S. Rugo

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology.

June 06, 2025

Vol.51 No.22

By Jacquelyn Cobb

Clinical Trials & Tribulations

Bridging the gaps in cancer care for Hispanics: Striving for equity and fairness in scientific advancements

Our Hispanic community is a vibrant and essential part of the American tapestry, contributing richly to the country’s society, culture, and economy. Yet, when it comes to healthcare, this community grapples with significant disparities, especially in cancer care.

Harmon Eyre, former ACS chief medical and scientific officer, dies at 84

Harmon Eyre, MD, died on May 31 in Salt Lake City. He was 84 years old. From 1993 to 2008, he served as the chief medical and scientific officer (CMSO) of the American Cancer Society.

June 06, 2025

Vol.51 No.22

By Otis W. Brawley

SRI International awarded contract for NCI PREVENT program

YOU MAY BE INTERESTED IN

In The Headlines: Increasing incidence of early-onset cancer is “a paradigm shift oncology isn’t quite prepared for”

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

Reimagining cancer care for a new generation of patients

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

Bridging the gaps in cancer care for Hispanics: Striving for equity and fairness in scientific advancements

Harmon Eyre, former ACS chief medical and scientific officer, dies at 84

Renew today!

Subscriber content

Never miss an issue!

Login

SRI International awarded contract for NCI PREVENT program

YOU MAY BE INTERESTED IN

In The Headlines: Increasing incidence of early-onset cancer is “a paradigm shift oncology isn’t quite prepared for”

Young women are now diagnosed with cancer at twice the rate of young menThe face of cancer is changing at a time when research is plagued by existential threats

Reimagining cancer care for a new generation of patients

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher findsCells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

Bridging the gaps in cancer care for Hispanics: Striving for equity and fairness in scientific advancements

Harmon Eyre, former ACS chief medical and scientific officer, dies at 84

Never miss an issue!

Login

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response